Chembio Submits Veterinary Tuberculosis Test To USDA; Initial Product Targeting Pharmaceutical Research Operations
Chembio Diagnostics, Inc. today announced that it submitted the Company’s first application to the U.S. Department of Agriculture (“USDA”) for PrimaTB Stat Pak, a rapid test to detect tuberculosis (TB) in non-human primates (NHPs).
Chembio will manufacture and market the product as it has previously announced pursuant to its exclusive license agreement with Sequella Corporation. The test will be directly marketed by Chembio to a targeted group of pharmaceutical research operations. Chembio believes that this product will address a need that these operations have for a more cost-effective and reliable means of TB testing. It is estimated that several hundred thousand NHPs are actively used in biomedical research in the US and Europe, but an increasing number of public health crises have led to a shortage of NHPs and a corresponding increase in their cost. TB can devastate colonies of NHPs, has a high fatality rate, and is easily transmitted to humans. Current diagnostic methods are extremely difficult to administer, costly and unreliable. The many false positive readings often result in euthanizing these expensive NHPs unnecessarily.
ABOUT CHEMBIO
Chembio Diagnostics, Inc. (Chembio) possesses expertise in the development and manufacturing of rapid test products for various indications, including HIV, Tuberculosis and BSE (a.k.a. Mad Cow Disease). References to Chembio Diagnostics, Inc. may actually refer to Chembio Diagnostic Systems, Inc., the 100%-owned subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY 11763. Chembio’s telephone number is 631-924-1135. Email can be directed to info@chembio.com . Additional information can be found at www.chembio.com .
